Literature reviews  >  Articles for review > Zenilman et al. LCR testing for gonorrhea and... 

 

About SDI
Mission
Diagnostic
Priorities
Workplan
Activities
Newsletters
Grants
Publications
Journal articles
Guidelines
Manuals
Reports
Literature reviews
Contact us

Repeat testing of positive samples from a low prevalence population will increase specificity and reduce the incidence of false positive test results.

LCR testing for gonorrhea and chlamydia in population surveys and other screenings of low prevalence populations: coping with decreased positive predictive value.
Zenilman JM, Miller WC, Gaydos C, Rogers SM, Turner CF.
Sexually Transmitted Infections 2003;79:94-97
 

Summary:

Question
What is the predictive value for a single positive ligase chain reaction test in a population survey in which positive specimens were retested?

Design
In a population survey that employed ligase chain reaction tests (LCR) to diagnose gonococcal and chlamydial infections, positive predictive values (PPV) were estimated based on a single LCR test. The theoretically predicted PPV for a single testing was compared with the results obtained when positive LCR tests were retested for confirmation.

Participants
Five hundred seventy-nine participants in a population based cross sectional household survey of adults residing in Baltimore, MD (Baltimore STD and Behavioral Survey), who were between 18 and 35 years old and provided a urine specimen, were tested.

Description of Tests and Diagnostic Standard
Urine specimens were tested for N. gonorrhoeae and C. trachomatis by LCR (LCx, Abbott Laboratories, Abbott Park, IL) following the procedures detailed by the manufacturer. All tests in the indeterminate optical density range were retested to provide a first test result. Specimens positive on the first LCR testing were retested using the same urine specimen and assay. Participants were considered positive if both the initial and confirmatory LCR tests were positive.

The PPV, expressed in a form based on Bayes' theorem, permits the prediction of PPV across a range of prevalences for a test with known sensitivity and specificity. Plots were constructed of the predicted PPV across a range of plausible values for prevalence (0.5%)-10%) and specificity (95.0%-99.9%). The PPVs were examined at a sensitivity of 95.0% and 88.6%.

Main Outcome Measures
The theoretically derived positive predictive value of a single PCR result was compared with the empirically observed PPV using a reference standard of confirmed positive result.

Main Results
Twenty (3.5%) and 39 (6.7%) participants were initially positive for C. trachomatis and N. gonorrhoeae, respectively. Repeat tests were unavailable for two specimens that were initially N. gonorrhoeae positive and one specimen initially positive for both organisms. Retests yielded positive results in 17 of 19 cases of chlamydial infection and 30 of 36 gonorrhea cases, reducing the prevalence of confirmed chlamydial and gonococcal infections to 17 (3.0%) and 30 (5.2%) of 576 participants, respectively. The PPV of the first LCR test was 89.5% for chlamydial and 83.3% for gonococcal infections.

The theoretical PPV of a single LCR test at 99.0% specificity and 95.0% sensitivity was 66% if the prevalence was 2%, and 32% if the prevalence was 0.5%. If the specificity increased to 99.9%, the PPV was 95.1% at 2% prevalence, and 82.6% at 0.5% prevalence. Assuming specificities for a single LCR test to be 99.0-99.6%, the theoretically expected PPV would be 73-87% for a single chlamydia test, and 82-92% for a single gonococcal test. This theoretical expectation is in agreement with the empirical results.

Authors' Conclusions
False positive results are predicted by Bayes' theorem and are statistically unavoidable unless test specificity is 100%. The number of false positive observed in this study using repeat LCR testing were predicable based on test performances and the low prevalence of infection in the population.

Source of funding: United States National Institutes of Health; Research Triangle Institute; Clinical Associate Physician Program of the General Clinical Research Center, Division of Research Resources, NIH; Abbott Laboratories.

For correspondence: Jonathan Zenilman, Infectious Diseases Division, Johns Hopkins University School of Medicine, Baltimore, MD. E-mail address: jzenilman@jhmi.edu.

   

about SDI | newsletters | grants | publications | literature reviews

WHO Home - WHO Search - TDR Home - SDI Home - SDI Contact us
(c) WHO/OMS 2001